High dose budesonide rectal foam + Low dose budesonide rectal foam + Matching placebo rectal foam
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Ulcerative Colitis
Conditions
Ulcerative Colitis
Trial Timeline
Jun 1, 2027 → Jan 1, 2030
NCT ID
NCT05976802About High dose budesonide rectal foam + Low dose budesonide rectal foam + Matching placebo rectal foam
High dose budesonide rectal foam + Low dose budesonide rectal foam + Matching placebo rectal foam is a approved stage product being developed by Bausch Health for Ulcerative Colitis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05976802. Target conditions include Ulcerative Colitis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05976802 | Approved | Recruiting |
Competing Products
20 competing products in Ulcerative Colitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mirikizumab SC + Mirikizumab IV + Placebo SC | Eli Lilly | Phase 3 | 77 |
| Mirikizumab | Eli Lilly | Phase 2 | 52 |
| Azathioprine + Placebo | Celltrion | Approved | 85 |
| CT-P13 SC (Infliximab) | Celltrion | Phase 3 | 77 |
| Afimkibart + Placebo | Chugai Pharmaceutical | Phase 3 | 77 |
| Tacrolimus | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + Placebo | Astellas Pharma | Phase 3 | 77 |
| Filgotinib Maleate | Eisai | Approved | 85 |
| AJM300 + Placebo | Eisai | Phase 3 | 77 |
| GSK3050002 + Placebo | Eisai | Phase 1 | 33 |
| adalimumab + placebo | Eisai | Phase 3 | 77 |
| E6007 + Placebo | Eisai | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 2 | 52 |
| KHK4083 + Placebo | Kyowa Kirin | Phase 1 | 33 |
| Arm1 + Arm 2 | Zydus Lifesciences | Phase 2 | 52 |
| Mirikizumab + Mirikizumab | Eli Lilly | Phase 3 | 77 |
| Mirikizumab IV + Mirikizumab SC + Vedolizumab IV + Placebo IV + Placebo SC | Eli Lilly | Phase 3 | 77 |
| LY3471851 + Placebo | Eli Lilly | Phase 2 | 52 |
| Mirikizumab + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4268989 + Placebo | Eli Lilly | Phase 2 | 52 |